INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH *et al.*	
	Filed: 2/25/2006	Group: 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,377,584	3/22/1983	Rasmusson *et al.*	424	258	
	A2	4,760,071	7/26/1988	Rasmusson *et al.*	514	284	
	A3	5,017,568	5/21/1991	Holt *et al.*	514	173	
	A4	5,096,890	3/17/1992	Cross *et al.*	514	422	
	A5	5,155,107	10/13/1992	Panzeri *et al.*	514	232.8	
	A6	5,233,053	8/3/1993	Cross *et al.*	548	568	
	A7	5,403,847	4/4/1995	Gluchowski *et al.*	514	318	
	A8	5,565,467	10/15/1996	Batchelor *et al.*	514	284	
	A9	5,578,611	11/26/1996	Gluchowski *et al.*	514	318	
	A10	5,595,985	1/21/1997	Labrie	514	169	
	A11	5,780,485	7/14/1998	Gluchowski *et al.*	514	318	
	A12	5,990,128	11/23/1999	Gluchowski *et al.*	514	318	
	A13	6,015,819	1/18/2000	Gluchowski *et al.*	514	318	
	A14	6,274,583	8/14/2001	Patane *et al.*	514	255	
	A15	6,376,503	4/23/2002	Patane *et al.*	514	274	
	A16	6,410,554	6/25/2002	Broten *et al.*	514	299	
	A17	6,423,719	7/23/2002	Lawyer	514	263	
	A18	2001/0044438	11/22/2001	Wyllie	514	252.17	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES | NO
	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54	|
	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08	|

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH *et al.*	
	Filed: 2/25/2006	Group: 1617

	B3	EP 0 572 165	12/1/1993	EPO	C07J	73/00	
	B4	EP 0 572 166	12/1/1993	EPO	C07J	73/00	
	B5	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
	B6	EP 1 123 705	8/16/2001	EPO	A61K	31/505	
	B7	GB 940,540	10/30/1963	UK	C07C		
	B8	WO 93/23038	11/25/1993	PCT	A61K	31/435	
	B9	WO 93/23039	11/25/1993	PCT	A61K	31/435	
	B10	WO 93/23040	11/25/1993	PCT	A61K	31/435	
	B11	WO 93/23041	11/25/1993	PCT	A61K	31/435	
	B12	WO 93/23048	11/25/1993	PCT	A61K	31/45	
	B13	WO 93/23050	11/25/1993	PCT	A61K	31/495	
	B14	WO 93/23051	11/25/1993	PCT	A61K	31/495	
	B15	WO 93/23376	11/25/1993	PCT	C07D	215/00	
	B16	WO 93/23419	11/25/1993	PCT	C07J	73/00	
	B17	WO 93/23420	11/25/1993	PCT	C07J	73/00	
	B18	WO 96/40136	12/19/1996	PCT	A61K	31/445	
	B19	WO 98/05641	2/12/1998	PCT	C07D	211/46	
	B20	WO 98/57638	12/23/1998	PCT	A61K	31/445	
	B21	WO 99/57131	11/11/1999	PCT	C07H	21/04	
	B22	WO 01/21167	3/29/2001	PCT	A61K	31/13	
	B23	WO 02/44151	6/6/2002	PCT	C07D	209/48	
	B24	WO 03/084928	10/16/2003	PCT	C07D	209/48	
	B25	WO 2004/004629	1/15/2004	PCT	A61K		
	B26	WO 2004/014853	2/19/2004	PCT	C07D	209/02	
	B27	WO 2004/018422	3/4/2004	PCT	C07D	209/52	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH *et al.*	
	Filed: 2/25/2006	Group: 1617

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)		
	C1	Berry et al., "The development of Human Benign Prostatic Hyperplasia With Age", *The Journal of Urology,* 132:474-479 (1984)
	C2	Speakman, "Initial Choices and Final Outcomes in Lower Urinary Tract Symptoms", *European Urology,* 40(Suppl. 4):21-30 (2001)
	C3	Shapiro et al., "The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostate Hyperplasia", *The Journal of Urology,* 147:1293-1297 (1992)
	C4	Caine, "The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy", *The Journal of Urology,* 136:1-4 (1986)
	C5	Andersson, "Mode of action of α_1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms", *BJU International,* 85(Suppl. 2):12–18 (2000)
	C6	Wilde and Goa, "Finasteride: An Update of its Use in the Management of Symptomatic Benign Prostatic Hyperplasia", *Drugs,* 57(4):557-581 (1999)
	C7	Chapple, "α-adrenergic blocking drugs in bladder outflow obstruction: what potential has α_1-adrenoceptor selectivity?", *British Journal of Urology,* 76(Suppl. 1):47-55 (1995)
	C8	Kawabe and Niijima, "Use of an α_1-Blocker, YM-12617, in Micturition Difficulty", *Urologia Internationalis,* 42:280-284 (1987)
	C9	Lepor et al., "A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia", *The Journal of Urology,* 148:1467-1474 (1992)
	C10	Reuther and Aagaard, "α-Adrenergic Blockade in the Diagnosis of Detrusor Instability Secondary to Infravesical Obstruction", *Urologia Internationalis,* 39:312-313 (1984)
	C11	Serels and Stein, "Prospective Study Comparing Hyoscyamine, Doxazosin, and Combination Therapy for the Treatment of Urgency and Frequency in Women", *Neurourology and Urodynamics,* 17(1):31-36 (1998)
	C12	Schwinn et al., "Cloning and Pharmacological Characterization of Human *Alpha*-1 Adrenergic Receptors: Sequence Corrections and Direct Comparison with Other Species Homologues", *The Journal of Pharmacology and Experimental Therapeutics,* 272(1):134-142 (1995)
	C13	Hieble et al., "International Union of Pharmacology X. Recommendation for Nomenclature of α_1-Adrenoceptors: Consensus Update", *Pharmacological Reviews,* 47(2):267-270 (1995)
	C14	Goepel et al., "Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate", *Urological Research,* 25(3):199-206 (1997)
	C15	Hieble et al., "In vitro characterization of the α-adrenoceptors in human prostate", *European Journal of Pharmacology,* 107(2):111-117 (1985)
	C16	Chapple et al., "Characterisation of Human Prostatic Adrenoceptors using Pharmacology Receptor Binding and Localisation", *British Journal of Urology,* 63:487-496 (1989)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH *et al.*	
	Filed: 2/25/2006	Group: 1617

	C17	Price et al., "Identification, Quantification, and Localization of mRNA for Three Distinct Alpha$_1$ Adrenergic Receptor Subtypes in Human Prostate", *The Journal of Urology,* 150:546-551 (1993)
	C18	Forray et al., "The α_1-Adrenergic Receptor that Mediates Smooth Muscle Contraction in Human Prostate Has the Pharmacological Properties of the Cloned Human α_{1C} Subtype", *Molecular Pharmacology,* 45:703-708 (1994)
	C19	Lepor et al., "A Comparison of the Binding and Functional Properties of *Alpha*-1 Adrenoceptors and Area Density of Smooth Muscle in the Human, Canine and Rat Prostates", *The Journal of Pharmacology and Experimental Therapeutics,* 270(2):722-727 (1994)
	C20	Muramatsu et al., "Pharmacological characterization of α_1-adrenoceptor subtypes in the human prostate: functional and binding studies", *British Journal of Urology,* 74:572-578, (1994)
	C21	Daniels et al., "Human cloned α_{1A}-adrenoceptor isoforms display α_{1L}-adrenoceptor pharmacology in functional studies", *European Journal of Pharmacology,* 370:337-343 (1999)
	C22	Oesterling, "The Origin and Development of Benign Prostatic Hyperplasia An Age-Dependent Process", *Journal of Andrology,* 12(6):348-355 (1991)
	C23	Michel, "Potential Role of α_1-Adrenoceptors in the Aetiology of LUTS", *European Urology Supplements,* 1(9):5-13 (2002)
	C24	Hieble and Ruffolo, Jr., "Recent advances in the identification of α_1- and α_2-adrenoceptor subtypes: therapeutic implications", *Expert Opinion on Investigational Drugs,* 6(4):367-387 (1997)
	C25	Young et al., "Congenital obstruction of the posterior urethra", *The Journal of Urology,* 167:265-267 (2002)
	C26	Staskin et al., "Overview Consensus Statement", *Urology,* 60(Suppl. 5A):1-6 (2002)
	C27	Caulfield and Birdsall, "International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors", *Pharmacological Reviews,* 50(2):279-290 (1998)
	C28	Hegde and Eglen, "Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Urinary Bladder", *Life Sciences,* 64(6/7):419-428 (1999)
	C29	Fetscher et al., "M_3 muscarinic receptors mediate contraction of human urinary bladder", *British Journal of Pharmacology,* 136(5):641-644 (2002)
	C30	Yamanishi et al., "Which muscarinic receptor is important in the bladder?", *World Journal of Urology,* 19(5):299-306 (2001)
	C31	Sullivan and Abrams, "Pharmacological Management of Incontinence", *European Urology,* 36(Suppl. 1):89-95 (1999)
	C32	Lozewicz, "Bladder outflow obstruction induced by ipratropium bromide", *Postgraduate Medical Journal,* 65(762):260-261 (1989)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH *et al.*	
	Filed: 2/25/2006	Group: 1617

	C33	Abrams et al., "Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity", *European Urology Supplements,* 1:132, Abstract 520 (2002)
	C34	Bundgaard, H. (ed.). (1995). *Design of Prodrugs.* Elsevier.
	C35	Michel et al., "Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α_1-adrenoceptor subtypes and in human prostate", *Journal of Autonomic Pharmacology,* 16:21-28 (1996)
	C36	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", *Life Sciences,* 64(25):2351-2358 (1999)
	C37	Jeppesen et al., "1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.$0^{2,6}$]heptanes as New Potent Muscarinic M_1 Agonists: Structure-Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives", *Journal of Medicinal Chemistry,* 42(11):1999-2006 (1999)
	C38	Kenny et al., "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia," *Journal of Medicinal Chemistry,* 40(9):1293-1315 (1997)
	C39	Athanasopoulos et al., "Combination Treatment with an α-Blocker Plus an Anticholinergic for Bladder Outlet Obstruction: A Prospective, Randomized, Controlled Study", *The Journal of Urology,* 169:2253-2256 (2003)
	C40	Ranjan et al., "Comparative study of human steroid 5α-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride", *Life Sciences,* 71(2):115-126 (2002)
	C41	Andriole and Kirby, "Safety and Tolerability of the Dual 5α-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia", *European Urology,* 44(1):82-88 (2003)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.